Stocktoria

Axogen, Inc. AXGN

Nasdaq · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 1986-12-17

Axogen, Inc. (AXGN) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $225.2M at a -7.0% net margin.

Chart by TradingView
38/100
Stocktoria Quality Score · grade D
5/9
Piotroski F — financial health
-0.43
Altman Z″ — distress risk · distress
Dividend yield · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 6 5 3 2 3 2 3 6 5 2016201720182019202020212022202320242025
Altman Z″
-4.31 -2.55 13.42 5.86 1.57 0.04 -1.73 -2.48 -1.47 -0.43 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$49.67 as of 2026-08-01 · +207.7% 1y
$16.14$49.6752-wk
Market cap USD$2.4B
Net margin 5y avg-13.6%
Return on equity 5y avg-19.4%
Beta1.12
Employees622

Analyst price target

$50.78 +2.2% vs last
· 9 analysts
target range $48.00 – $55.00 · median $50.00
2 strong buy · 7 buy ·
Recent analyst actions
DateFirmRating
2026-04-29Canaccord GenuityBuy (main)
2026-04-29CitizensMarket Outperform (main)
2026-04-29Wells FargoOverweight (main)
2026-04-29HC Wainwright & Co.Buy (main)
2026-04-23Lake StreetBuy (main)
2026-03-30Canaccord GenuityBuy (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 63%
Net marginstronger than 43%
Return on equitystronger than 47%
Revenue growthstronger than 80%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 5/9 tests passed

Altman Z″ components · distress zone

ComponentValue
Working capital / assets0.437
Retained earnings / assets-1.385
EBIT / assets-0.035
Equity / liabilities1.388

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
AXGNAxogen, Inc.5/9-0.43+20.2%
OMOutset Medical, Inc.6/9-9.87+5.1%
BLFSBIOLIFE SOLUTIONS INC6/910.32+28.9%
VASOVASO Corp6/90.7221.3+2.7%
CBLLCeribell, Inc.3/93.97+36.1%
FOCLEDAP TMS SA3/9-5.4+1.6%
ELMDElectromed, Inc.6/910.9946.4+17%

All Manufacturing companies →

About Axogen, Inc.

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

FAQ

Is AXGN financially healthy?

Axogen, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.

Does AXGN pay a dividend?

No, Axogen, Inc. does not currently pay a dividend.

How profitable is AXGN?

In FY2025, Axogen, Inc. had a net margin of -7.0% and a return on equity of -12.2%.

What is the analyst price target for AXGN?

The average Wall-Street price target for Axogen, Inc. is $50.78, about 2.2% above the recent price, from 9 analysts.

Is AXGN a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Axogen, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.